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A b s t r a c t
Introduction: The aim of the study was to compare adalimumab or golimum-
ab with infliximab in patients with moderately-to-severely active ulcerative 
colitis (UC).
Material and methods: This paper was prepared according to the PRISMA 
guidelines. The systematic literature search was performed in PubMed, Em-
base, and Cochrane Library. No direct head-to-head comparisons for inflix-
imab vs. adalimumab or golimumab were available so an indirect compar-
ison according to the Bucher method was performed after a homogeneity 
evaluation of the included studies. 
Results: Six RCTs were included in the systematic review. An indirect com-
parison was performed, which revealed that infliximab was more effective 
in inducing clinical response compared with both doses of adalimumab 
(160/80 mg or 80/40 mg; p < 0.05), and, in clinical remission, infliximab was 
more effective than adalimumab (only for a dosage regime of 80/40 mg; 
p < 0.05). No statistically significant differences in clinical response and clin-
ical remission were observed between infliximab and golimumab in the in-
duction phase. A significant (p < 0.05) advantage only of infliximab compared 
with adalimumab at doses of 80/40 mg and 80/160 mg was seen in terms of 
clinical response in the maintenance phase (up to 52–54 weeks). The indirect 
comparison revealed that serious adverse events were significantly more fre-
quent among patients treated with a maintenance dose of 100 mg of golim-
umab compared with those treated with infliximab (p < 0.05). 
Conclusions: No significant differences in efficacy in the maintenance phase 
between infliximab and golimumab or adalimumab were revealed. Infliximab 
proved to be more effective than adalimumab but of similar efficacy to that 
of golimumab in the induction phase.
Key words: infliximab, adalimumab, golimumab, ulcerative colitis, biological 
therapy, systematic review, indirect comparison.
Introduction
Ulcerative colitis (UC) is a type of inflammatory bowel disease that af-
fects the mucosa of the colon [1–3], usually diagnosed at the age of 20 to 
30 years, and is always a chronic life-long condition [4]. The condition is 
more and more common worldwide, especially in highly developed soci-
eties, and its prevalence varies by geographic region, ranging from 4.9 to 
505 per 100 000 in Europe, 4.9 to 168.3 per 100 000 in Asia and the Mid-
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dle East, and 37.5 to 248.6 per 100 000 in North 
America [3, 4]. The fact that the highest incidence 
and prevalence of UC are in the populations of Eu-
rope and North America is considered to be linked 
to genetic factors, environment, and lifestyle, par-
ticularly to a  diet high in fat and sugar, alcohol, 
medication use, stress, and high socioeconomic 
status [1, 3, 5–12]. The goal of therapy in UC is to 
induce and maintain remission, improve quality of 
life, and prevent colectomy [13–15].
Conventional therapy of ulcerative colitis in-
cludes corticosteroids and immunosuppressives 
(e.g. azathioprine, methotrexate); in the case of 
lack of such therapy, biologic treatment should 
be introduced; moreover, in some patients there 
is no clinical improvement after pharmacothera-
py, so surgery (colectomy) has to be performed. 
Immunosuppressives have limited efficacy due to 
inadequate control of the disease, especially in 
patients with more advanced disease, and this is 
often associated with the risk of intolerance or re-
sistance to concurrent treatment [3, 13]. Because 
of that and the increasing prevalence of UC [5], 
identification of an alternative and more effec-
tive treatment is crucial to increase the number of 
available therapeutic options and to improve clini-
cal outcomes [3]. In a number of patients a biolog-
ic therapy is used with tumor necrosis factor (TNF) 
antagonists; among them infliximab is the most 
commonly used; other potentially useful mono-
clonal antibodies for UC include adalimumab and 
golimumab [3]. Infliximab, adalimumab and goli-
mumab have been approved for the treatment of 
UC by the U.S. Food and Drug Administration (FDA) 
and the European Medicines Agency (EMA) [16, 
17]; infliximab was the first biologic agent autho-
rized in the therapy of UC; currently it is very often 
used for this indication, usually in the first stage 
of biologic therapy; adalimumab and golimumab 
are newer alternatives; the most recent, golimum-
ab, was introduced in the European Union for this 
indication in 2013. Infliximab, adalimumab, and 
golimumab are antagonists of the TNF. All of them 
bind soluble and transmembrane TNF, neutralizing 
TNF activity and inhibiting binding to TNF recep-
tors. In addition, infliximab and adalimumab are 
responsible for the induction of activated T cells 
and macrophage apoptosis; adalimumab also ly-
ses TNF-expressing cells by complement-depen-
dent cytotoxicity [3, 18–20]. 
Therefore, the aim of this systematic review 
was to evaluate the clinical efficacy and safety of 
newer biologic drugs (adalimumab and golimum-
ab) in comparison with infliximab in patients with 
moderately-to-severely active UC. Owing to the 
lack of evidence from head-to-head studies com-
paring different biologics, an indirect method may 
provide useful information about their relative 
efficacy. Therefore, we applied a  valid, adjusted 
indirect comparison assessment according to the 
Bucher method, being one of the most suitable 
approaches for indirect treatment comparisons of 
randomized controlled trials (RCTs). This method 
is based on the assumption that indirect evidence 
is consistent with the direct comparison. It is also 
based on a meta-analysis but compares the value 
of treatment effects in RCTs of the interventions 
in comparison with placebo or a  control group. 
Supposing that treatments A and C are compared 
in one RCT, and treatments B and C are compared 
in another RCT, then the indirect comparison of 
A  and B is adjusted according to the results of 
their direct comparisons with a  common inter-
vention (comparator) – C [21, 22]. In our previous 
study, we analyzed the efficacy and safety of bi-
ologic drugs in comparison with placebo for the 
treatment of active UC [3]. Currently, we would 
like to perform further research to investigate the 
difference between biologics with the best meth-
od available – an indirect comparison. 
Material and methods
Search strategy and study selection
As described in detail previously [3] the sys-
tematic review was conducted and reported ac-
cording to the methods and recommendations 
from the Preferred Reporting Items for Systematic 
Reviews and Meta-Analysis (PRISMA) Statement 
[23] and the Cochrane Handbook [24]. The sys-
tematic literature review was conducted using the 
main electronic databases, Medline via PubMed, 
Embase, and the Cochrane Central Register of 
Controlled Trials, until 27 November 2014. The key 
words ulcerative colitis (population) and inflix-
imab or adalimumab or golimumab (intervention) 
were used to find relevant citations. Only English, 
French, and German publications were includ-
ed. The search strategy was presented with the 
QUOROM diagram (Figure 1). Two reviewers inde-
pendently conducted the search and selection of 
studies on the basis of the previously established 
inclusion criteria. The decision for inclusion was 
made by consensus to reach the final decision. 
The Clinical Trials Register (www.clinicaltrials.gov) 
was searched for unpublished or ongoing trials. 
Compared datasets included data only from 
randomized, double-blind, placebo-controlled, and 
parallel trials of phase II/III studies. Results from 
nonrandomized or uncontrolled open-label stud-
ies were not incorporated into the dataset [25]. 
The population of interest comprised adults with 
moderately-to-severely active UC (confirmed by 
biopsy and defined as a Mayo score ranging from 
6 to 12 points with an endoscopy subscore of at 
least 2) despite concurrent treatment with stable 
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doses of oral corticosteroids or immunomodula-
tors (such as azathioprine or 6-mercaptopurine), 
or both. Patients concurrently treated with oral 
corticosteroids or immunomodulators were re-
ceiving a stable dose prior to baseline. Concurrent 
therapy was not required for patients who failed 
to respond to or could not tolerate previous corti-
costeroid or immunomodulator treatment, as as-
sessed by the investigator. Patients who received 
infliximab, adalimumab, golimumab, or any other 
anti-TNF therapy in the past were not eligible. The 
key exclusion criteria included a history of colecto-
my or planned bowel surgery, ongoing infections 
(in particular confirmed tuberculosis), or use of 
any investigational agent within 30 days or five 
half-lives prior to baseline.
Results from the included studies were ana-
lyzed separately for the induction phase (data ex-
tracted at 6 to 8 weeks) and maintenance phase 
(data extracted at 52 to 54 weeks of treatment).
Studies with efficacy or safety assessments 
made after 54 weeks of treatment were excluded 
from the analysis [26, 27]. Furthermore, studies 
with different definitions of clinical response and 
clinical remission were not included [25, 27–30]. 
Conference abstracts were excluded owing to the 
lack of appropriate data and detailed information 
regarding methodology and obtained results.
Data extraction and quality assessment
All data were extracted by P.K. and then 
checked by A.P. The extracted data contained 
patients’ characteristics, study design, drug dos-
es, duration of treatment, outcome measures/
definition of endpoints, proportion of participants 
achieving particular predefined endpoints, and 
the number of any adverse events and serious 
adverse events during treatment. Data included 
in the indirect comparison were extracted from 
trial groups that adhered to the dose regimens ap-
proved by the EMA. Trials with unapproved dose 
regimens were excluded from the analysis. The 
exception was an adalimumab dose of 80/40 mg, 
which was not consistent with the dose regimens 
approved by the EMA, but was also included in the 
data analysis. This was because, according to the 
reference publication [31], the study protocol had 
been expanded to include two dose regimens of 
adalimumab: the first adhered to that approved by 
the EMA, and the second was ADA80/40, namely, 
80 mg at week 0 and 40 mg at weeks 2, 4 and 6. 
The same doses of adalimumab were also used 
in another clinical trial [32]. In cases of multi-arm 
placebo-controlled trials using infliximab and goli-
mumab, relevant data were extracted only for the 
arms with an approved regimen and the placebo 
arm. Different doses of the same biologic drug 
were regarded and presented as separate inter-
ventions. The  methodological quality of eligible 
RCTs was assessed using the Jadad scale [33].
Treatment regimen for biologic drugs
According to the registration status in the Eu-
ropean Union, the approved infliximab regimen 
for the treatment of active UC in adult patients is 
5 mg/kg of body mass administered at weeks 0, 2, 
Figure 1. Study flow diagram showing the results of the search and process of screening and selecting studies for 
inclusion in the indirect comparison
Records excluded on basis of title and abstract: 659
Full-text articles excluded, with reasons: 
N = 64 – retrospective analysis of included studies  
(no predefined endpoints)
N = 8 – pooled analysis of two or more trials
N = 5 – efavirenz included in every treatment arm
N = 1 – previously treated patients
Records identified through main 
database searching  
(PubMed 321; Embase 599; 
Cochrane 443)
Additional records identified 
through other sources 128
Records screened after duplicates removed: 766
Full-text articles assessed for eligibility: 107
Studies included in qualitative synthesis:  
34 RCTs described in 44 references
Studies included in quantitative synthesis  
(meta-analysis): 26 RCTs
Articles from hand searching of reference lists: 1
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and 6, followed by 5 mg/kg every 8 weeks [34]. 
The approved adalimumab regimen is 160 mg 
at week 0, followed by 80 mg at week 2, and 
40 mg every 2 weeks thereafter (patients who ex-
perience a decrease in their response may benefit 
from an increase in dosing frequency to 40 mg 
of adalimumab every week) [35]. The approved 
golimumab regimen is 200 mg and 100 mg at 
weeks 0 and 2, respectively, followed by 50 mg (or 
100 mg for patients weighing over 80 kg) every 
4 weeks [36]. 
Outcomes
The primary efficacy outcomes were the per-
centage of patients achieving clinical remission 
and clinical response after both the induction 
phase (6–8 weeks) and maintenance phase of 
drug administration (52–54 weeks). Clinical remis-
sion was defined as a Mayo score of 2 or fewer 
points, with no individual subscore greater than 
1 point, while clinical response was defined as 
a decrease from the baseline value (observed in 
the preceding induction phase) in the Mayo score 
by 30% or more and 3 or more points, with ei-
ther a decrease in the rectal bleeding subscore of 
1 or more or a rectal bleeding subscore of 0 or 1 
point. The safety analysis of the treatment with 
TNF-α inhibitors was based on the incidence of 
any adverse events and serious adverse events 
occurring during maintenance treatment (up to 
52–54 weeks).
Indirect comparison 
Using the extracted data we prepared an ad-
justed indirect comparison using random- or 
fixed-effects models depending on the heteroge-
neity of the analyzed population. The heterogene-
ity test based on the Cochrane Q statistic estima-
tion was used; when the compared populations 
were homogeneous (Coch ane Q test p > 0.1), 
the inverse variance fixed-effects model was used 
in a meta-analysis, and when the compared pop-
ulations were heterogeneous (Cochrane Q test 
p ≤ 0.1), the DerSimonian and Laird random-ef-
fects model was applied. We obtained compara-
tive relative risks with 95% confidence intervals 
for prespecified outcomes and adverse events. 
Results
Identified studies
The systematic review revealed six RCT studies 
that met our inclusion criteria. The results of these 
six clinical trials were presented in nine publica-
tions: one of these RCTs used infliximab vs. place-
bo [37, 38]; four used adalimumab vs. placebo [31, 
32, 39–41]; and two used golimumab vs. placebo 
[42, 43] in the treatment of UC. Table I  summa-
rizes the characteristics of trials included in the 
adjusted indirect comparison.
All biologic drugs in the included trials were 
compared with placebo, which was a  common 
comparator in the Bucher method. A  heteroge-
neity analysis of the included studies was also 
performed and revealed that they did not differ in 
terms of patients’ characteristics or the definition 
of selected endpoints such as clinical response 
and clinical remission. The studies were homoge-
neous enough to be used in the indirect compar-
ison (Table II).
The methodological quality of the included 
RCTs was evaluated as high (one trial [31] scored 
four points and the other five trials [32, 37–43] 
scored three points). All eligible trials were ran-
domized and double-blind. They also provided 
data on the number of patient withdrawals. 
Efficacy of biologic therapy (clinical 
response and clinical remission)
Indirect comparisons between different biologic 
treatments showed that during the induction phase 
of treatment, infliximab [37, 38] was more effec-
tive than adalimumab [31, 32, 39–41] given at both 
doses, namely, 160/80 mg and 80/40 mg (Table III). 
However, for the maintenance phase of treatment, 
no significant differences between infliximab [37, 
38] and adalimumab [31, 32, 39–41] were revealed 
(Figure 2; Table III). Furthermore, we did not observe 
any significant differences in clinical response be-
tween infliximab [37, 38] and golimumab [42, 43] 
in either the induction or the maintenance phase of 
drug administration (Figure 2; Table III). 
An indirect comparison analysis demonstrated 
that clinical remission during the induction phase 
was significantly more often observed among pa-
tients treated with infliximab [37, 38] than among 
those treated with adalimumab [31, 32, 39–41] 
given at a dose of 80/40 mg (Figure 2, Table III). 
Differences between infliximab [37, 38] and adali-
mumab [31, 32, 39–41] at a dose of 160/80 mg 
or golimumab [42, 43] were not revealed during 
the induction phase of treatment (Table III). Sim-
ilarly, the frequency of clinical remission among 
patients treated with infliximab [37, 38] or adali-
mumab [31, 32, 39–41] and those treated with in-
fliximab [37, 38] or golimumab [42, 43] at the end 
of the maintenance phase of treatment did not 
differ significantly (Figure 2; Table III). 
To summarize, our indirect comparison showed 
that in the maintenance phase of drug adminis-
tration, all tested biologic drugs presented similar 
efficacy measured by clinical response and clini-
cal remission rates. Moreover, the study revealed 
no significant difference between infliximab and 
golimumab in the induction phase of drug admin-
istration.
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Infliximab seems to have better efficacy than 
adalimumab (160/80/40 mg) in the induction 
phase of drug administration only in the case of 
clinical response, and we did not observe any sig-
nificant differences in clinical remission between 
these two drugs. 
In addition, due to the fact that the clinical re-
mission of the disease (defined as a  total Mayo 
score of 2 points or lower, with no individual sub-
score exceeding 1 point) is contained in the defi-
nition of clinical response (defined as a decrease 
from baseline in the total Mayo score of at least 
3 points and at least 30%, with an accompany-
ing decrease in the subscore for rectal bleeding of 
at least 1 point or an absolute subscore for rectal 
bleeding of 0 or 1), we decided to carry out an 
indirect comparison of the analyzed substances 
in the field of clinical response without clinical re-
mission.
The indirect comparison showed no significant 
difference in clinical response between infliximab 
[37, 38] or adalimumab [31, 32, 39–41] and inflix-
imab [37, 38] or golimumab [42] during the induc-
tion phase (6–8 weeks) (Figure 3; Table IV). Also, 
an indirect comparison of clinical response in the 
maintenance phase (up to 52–54 weeks) between 
infliximab [37, 38] or adalimumab [31, 32, 39–41] 
and infliximab [37, 38] or golimumab [42] showed 
no significant differences, except for a  significant 
advantage of infliximab at a dose of 5 mg [37, 38] 
over adalimumab at doses of 80 mg/40 mg [31, 32] 
and 80/160 mg [31, 32, 39–41] (Figure 3; Table IV). 
Safety of biologic therapy
We analyzed the incidence of any adverse 
events and serious adverse events occurring 
only during maintenance treatment (up to 52–54 
weeks) for all biologics because in publications 
describing studies of infliximab [37, 38], no data 
on adverse events in the induction phase of treat-
ment were available. Moreover, the safety profile 
assessment in the maintenance phase, that is, 
after a  longer period of drug administration, is 
more reliable and makes it possible to identify 
any, including rare or unexpected, adverse events 
of therapy and provides more accurate safety data 
than in a short follow-up.
Data used in the case of the safety profile as-
sessment of adalimumab have been presented in 
three publications [32, 39–41]; however, because 
of insufficient data for indirect comparison, some 
additional information was provided by the Clini-
calTrials.gov database [44].
The indirect comparison showed that there is 
no difference in the frequency of overall adverse 
events among patients treated with infliximab 
[37, 38] in comparison with those treated with 
adalimumab [32, 39–41] or golimumab [43] (Fig-
ure 4; Table V). In the case of patients treated with 
a maintenance golimumab dose of 100 mg [43], 
Table I. Studies included in the indirect comparison of infliximab vs adalimumab or golimumab
Trial (first author, publication year)  
[reference]
Treatment arms (only 
comparisons relevant to this 
meta-analysis are listed) 
Number of 
patients
Timing of outcome 
assessment [week]
ACT 1, ACT 2 (Rutgeerts, 2005 [37]; 
Sandborn, 2009 [38])
IFX 5 mg 242/121 8 and 54
Placebo 244/123
Suzuki, 2014 [32] ADA 160/80 mg 90 8 and 52
ADA 80/40 mg 87
Placebo 96
ULTRA 2 (Sandborn, 2012 [39];  
Sandborn, 2013 [40];  
Feagan, 2014 [41])
ADA 160/80 mg 248 8 and 52
Placebo 246
ULTRA 1 (Reinisch, 2011 [31];  
Feagan, 2014 [41])
ADA 160/80 mg 130 8
ADA 80/40 mg 130
Placebo 130
PURSUIT-SC (Sandborn, 2014 [42]) GOL 200/100 mg 253 6
Placebo 251
PURSUIT-M (Sandborn, 2014 [43]) GOL 50 mg 154 52
GOL 100 mg 154
Placebo 156
IFX – infliximab, ADA – adalimumab, GOL – golimumab.
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Table III. Results of an adjusted indirect comparison between the efficacy of infliximab and adalimumab or inflix-
imab and golimumab
Variable 6–8 weeks 52–54 weeks
Clinical response  
(RR (95% CI))
Clinical remission  
(RR (95% CI))
Clinical response
(RR (95% CI))
Clinical remission  
(RR (95% CI))
Infliximab 5 mg vs. adalimumab 160/80 mg
Infliximab [37], [38] vs. 
adalimumab [31], [32], 
[39–41]
1.47 (1.15–1.87)  
p = 0.0022
2.35 (0.96–5.81)
p > 0.05
1.39 (0.82–2.33)
p > 0.05
1.03 (0.52–2.04)
p > 0.05
Infliximab 5 mg vs. adalimumab 80/40 mg
Infliximab [37], [38] vs. 
adalimumab [31], [32]
1.71 (1.28–2.28)
p = 0.0002
3.27 (1.25–8.57)
p = 0.0158
NA NA
Infliximab 5 mg vs. adalimumab 40 mg
Infliximab [37], [38] vs. 
adalimumab [31], [32], 
[39–41]
NA NA 1.36 (0.83–2.22)
p > 0.05
0.91 (0.49–1.69)
p > 0.05
Infliximab 5 mg vs. golimumab 200/100 mg
Infliximab [37], [38] vs. 
golimumab [42]
1.18 (0.88–1.59)
p > 0.05
1.34 (0.51–3.52)
p > 0.05
NA NA
Infliximab 5 mg vs. golimumab 100 mg
Infliximab [37], [38] vs. 
golimumab [43]
NA NA 1.44 (0.87–2.36)
p > 0.05
1.23 (0.64–2.33)
p > 0.05
Infliximab 5 mg vs. golimumab 50 mg
Infliximab [37], [38] vs. 
golimumab [43]
NA NA 1.52 (0.92–2.51)
p > 0.05
1.47 (0.76–2.84)
p > 0.05
Figure 2. Forest plot of direct estimates for: A  – infliximab (5 mg) vs. placebo and adalimumab (160/80 mg)  
vs. placebo, and indirect comparison between the treatments in the case of clinical remission after 6–8 weeks 
of drug administration; B – infliximab (5 mg) vs. placebo and adalimumab (160/80 mg) vs. placebo, and indirect 
comparison between treatments in the case of clinical remission after 52–54 weeks of drug administration; C – in-
fliximab (5 mg) vs. placebo and golimumab (200/100 mg) vs. placebo, and indirect comparison between treatments 
in the case of clinical remission after 6–8 weeks of drug administration; D – infliximab (5 mg) vs. placebo and go-
limumab (100 mg) vs. placebo, and indirect comparison between treatments in the case of clinical remission after 
52–54 weeks of drug administration
Infliximab vs. placebo 3.73 (1.68–8.31)
Adalimumab vs. placebo 1.58 (1.05–2.40)
Infliximab vs. adalimumab 160/80 mg 2.35 (0.96–5.81)
Infliximab vs. placebo 2.10 (1.31–3.36)
Adalimumab vs. placebo 2.03 (1.24–3.32)
Infliximab vs. adalimumab 160/80 mg 1.03 (0.52–2.04)
Infliximab vs. placebo 3.73 (1.68–8.31)
Golimumab vs. placebo 2.79 (1.62–4.80)
Infliximab vs. golimumab 200/100 mg 1.34 (0.51–3.52)
Infliximab vs. placebo 2.10 (1.31–3.36)
Golimumab vs. placebo 1.71 (1.10–2.66)
Infliximab vs. golimumab 100 mg 1.23 (0.64–2.33)
Forest (meta-analysis)
 0.5 1 2 5 10
A
B
C
D
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serious adverse events were significantly more 
frequent than in the case of patients treated with 
infliximab [37, 38] (Figure 4; Table V). 
Discussion 
Ulcerative colitis is a  relapsing disease that is 
difficult to treat, and a high percentage of patients 
are refractory to traditional medical management 
[45, 46]. As described in detail previously [3] the 
goal of therapy in patients with UC is the induction 
and maintenance of a clinical response and remis-
sion to prevent the risk of colectomy and possible 
complications related to this procedure, such as 
pouchitis, incontinence, or pelvic sepsis [47–49].
Anti-TNF-α monoclonal antibodies, such as go-
limumab, adalimumab, and infliximab, bind TNF, 
neutralizing its activity, and inhibit binding to TNF 
receptors [18–20]. As described previously [3] the 
efficacy of infliximab and adalimumab in the ther-
apy of patients with moderate-to-severe UC was 
proved in individual studies [29–31, 37–39, 44] as 
well as in the meta-analyses conducted by Law-
Figure 3. Forest plot of direct estimates for: A – infliximab (5 mg) vs. placebo and adalimumab (160/80 mg) vs. 
placebo, and indirect comparison between the treatments in the case of clinical response after 6–8 weeks of drug 
administration; B – infliximab (5 mg) vs. placebo and adalimumab (80/40 mg) vs.placebo, and indirect comparison 
between the treatments in the case of clinical response after 6–8 weeks of drug administration; C – infliximab 
(5 mg) vs. placebo and golimumab (200/100 mg) vs. placebo, and indirect comparison between treatments in the 
case of clinical response after 6–8 weeks of drug administration; D – infliximab (5 mg) vs. placebo and adalimumab 
(160/80 mg) vs. placebo, and indirect comparison between treatments in the case of clinical response after 52–54 
weeks of drug administration; E – infliximab (5 mg) vs. placebo and adalimumab (80/40) and (160/80) mg vs. 
placebo, and indirect comparison between treatments in the case of clinical response after 52–54 weeks of drug 
administration; F – infliximab (5 mg) vs. placebo and golimumab (50 mg) vs. placebo, and indirect comparison 
between treatments in the case of clinical response after 52–54 weeks of drug administration; G – infliximab  
(5 mg) vs. placebo and golimumab (100 mg) vs. placebo, and indirect comparison between treatments in the case 
of clinical response after 52–54 weeks of drug administration
Infliximab vs. placebo 1.33 (0.99–1.80)
Adalimumab vs. placebo 1.29 (1.00–1.66)
Infliximab vs. adalimumab 160/80 mg 1.04 (0.70–1.53)
Infliximab vs. placebo 1.33 (0.99–1.80)
Adalimumab vs. placebo 1.189 (0.91–1.53)
Infliximab vs. adalimumab 80/40 mg 1.13 (0.76–1.68)
Infliximab vs. placebo 1.33 (0.99–1.80)
Golimumab vs. placebo 1.41 (1.06–1.86)
Infliximab vs. golimumab 200/100 mg 0.95 (0.63–1.43)
Infliximab vs. placebo 3.25 (1.09–9.69)
Adalimumab vs. placebo 1.32 (0.80–2.18)
Infliximab vs. adalimumab 160/80 mg 2.46 (0.74–8.16)
Infliximab vs. placebo 3.25 (1.09–9.69)
Adalimumab vs. placebo 0.76 (0.35–1.64)
Infliximab vs. adalimumab 80/40 and 160/80 mg 4.28 (1.12–16.31)
Infliximab vs. placebo 3.25 (1.09–9.69)
Golimumab vs. placebo 1.60 (1.00–2.56)
Infliximab vs. golimumab 50 mg 2.04 (0.62–6.69)
Infliximab vs. placebo 3.25 (1.09–9.69)
Golimumab vs. placebo 1.46 (0.90–2.37)
Infliximab vs. golimumab 100 mg 2.22 (0.67–7.33)
Forest (meta-analysis)
 0.2 0.5 1 2 5 10 100
A
B
C
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son et al. [50] and Ford et al. [51], and which also 
demonstrated the superiority of infliximab over 
placebo in patients with moderate-to-severe UC. 
This systematic review and indirect compar-
ison has both limitations and strengths. One of 
the limitations was the lack of head-to-head stud-
ies comparing different biologics, so traditional 
methods could not be applied for the comparison. 
Therefore, we used the Bucher method to com-
pare the efficacy of biologics. The Bucher method 
is an indirect comparison of competing interven-
tions adjusted according to the results of their 
direct comparison with a  common intervention 
or placebo. The method can protect against some 
biases, and the advantage of RCTs can be at least 
partly preserved when an indirect comparison is 
used [21], although it is usually a worse and less 
credible analytic tool than a  head-to-head com-
parison in an RCT. It should be underlined that the 
results of indirect comparisons are characterized 
by limited reliability because such a comparison is 
always burdened with a certain methodical error 
that is impossible to omit in a comparison of two 
different clinical trials using a common compara-
tor [22]. An indirect analysis, although less reliable 
than a direct comparison, allows one to draw con-
clusions about the clinical effectiveness of the an-
alyzed therapeutic options, especially because if 
you manage to conduct a meta-analysis from the 
most homogeneous data of the identified clinical 
studies, it increases the number of patients taken 
into account and, therefore, influences the reliabil-
ity of the results. The results of the indirect com-
parison of infliximab vs. adalimumab, and inflix-
imab vs. golimumab, by the Bucher method had 
provided the most reliable data until the appear-
ance of head-to-head studies. A direct comparison 
trial between the drugs will be the best way to 
compare the clinical effectiveness and safety of 
the biologic therapy, but until such studies have 
been performed the indirect comparison is the 
only available method to compare the drugs; clini-
cal trials directly comparing the drugs are urgently 
needed.
As part of this study, a  possibility to conduct 
a mixed treatment comparison (MTC) instead of 
an indirect comparison was also considered. The 
MTC is a  statistical method that allows one to 
simultaneously compare numerous therapeutic 
options, taking into account the results of direct 
and indirect comparisons. It is used in the case 
of numerous alternative interventions; howev-
er, direct comparisons are only made between 
some of the interventions, and when the results 
of the indirect comparison do not allow one to 
reach unequivocal conclusions. Nevertheless, the 
use of the MTC is risky, because different studies 
included in a meta-analysis or systematic review 
are often clinically and methodically nonhomoge-
neous, so the results have very limited reliability 
[52]. Ultimately, we decided to use a more reliable 
method, namely, the indirect comparison accord-
ing to Bucher. Moreover, an MTC (also known as 
network meta-analysis) comparing the efficacy 
Table IV. Results of an adjusted indirect comparison between the efficacy of infliximab and adalimumab or inflix-
imab and golimumab in terms of clinical response
Variable 6–8 weeks 52–54 weeks
Clinical response 
(RR (95% CI))
Clinical response
(RR (95% CI))
Infliximab 5 mg vs. adalimumab 160/80 mg
Infliximab [37], [38] vs. 
adalimumab [31], [32], [39–41]
1.04 (0.70–1.53)
p > 0.05
2.46 (0.74–8.16)
p > 0.05
Infliximab 5 mg vs. adalimumab 80/40 mg
Infliximab [37], [38] vs. 
adalimumab [31], [32]
1.13 (0.76–1.68) 
p > 0.05
NA
Infliximab 5 mg vs. adalimumab 80/40 mg and 80/160 mg
Infliximab [37], [38] vs. 
adalimumab [31], [32], [39–41]
NA 4.28 (1.12–16.31)
p = 0.0331
Infliximab 5 mg vs. golimumab 200/100 mg
Infliximab [37], [38] vs. 
golimumab [42]
0.95 (0.63–1.43) 
p > 0.05
NA
Infliximab 5 mg vs. golimumab 100 mg
Infliximab [37], [38] vs. 
golimumab [43]
NA 2.22 (0.67–7.33) 
p > 0.05
Infliximab 5 mg vs. golimumab 50 mg
Infliximab [37], [38] vs. 
golimumab [43]
NA 2.04 (0.62–6.69)
p > 0.05
Paweł Kawalec, Andrzej Pilc
1106 Arch Med Sci 5, October / 2016
Figure 4. Forest plot of direct estimates for: A – infliximab (5 mg) vs. placebo and adalimumab (160/80 mg) vs. pla-
cebo, and indirect comparison between treatments in the case of serious adverse events after 52–54 weeks of drug 
administration; B – infliximab (5 mg) vs. placebo and golimumab (100 mg) vs. placebo, and indirect comparison 
between treatments in the case of serious adverse events after 52–54 weeks of drug administration
Infliximab vs. placebo 0.76 (0.53–1.08)
Adalimumab 160/80 vs. placebo 0.96 (0.64–1.42)
Infliximab vs. adalimumab 160/80 mg 0.80 (0.47–1.36)
Infliximab 5 mg vs. placebo 0.76 (0.53–1.08)
Golimumab 100 mg vs. placebo 1.86 (0.95–3.62)
Infliximab 5 mg vs. golimumab 100 mg 0.41 (0.19–0.87)
Forest (meta-analysis)
 0.1 0.2 0.5 1 2 5
A
B
Table V. Results of an adjusted indirect comparison between t he safety profile of infliximab and adalimumab or 
infliximab and golimumab
Variable 52–54 weeks
Adverse events
(RR (95% CI))
Serious adverse events  
(RR (95% CI))
Infliximab 5 mg vs. adalimumab 160/80 mg
Infliximab [37], [38] vs.
adalimumab [33], [39–41]
1.04 (0.94–1.16) 
p > 0.05
0.80 (0.47–1.36)
p > 0.05
Infliximab 5 mg vs. adalimumab 80/40 mg
Infliximab [37], [38] vs.
adalimumab [32]
0.96 (0.79–1.16) 
p > 0.05
0.59 (0.27–1.31) 
p > 0.05
Infliximab 5 mg vs. golimumab 100 mg
Infliximab [37], [38] vs.
golimumab [43]
0.96 (0.81–1.14) 
p > 0.05
0.41 (0.19–0.87) 
p = 0.0205
Infliximab 5 mg vs. golimumab 50 mg
Infliximab [37], [38] vs.
golimumab [43]
0.97 (0.82–1.15)
p > 0.05
0.69 (0.30–1.59) 
p > 0.05
and harm of adalimumab, golimumab, infliximab, 
and vedolizumab in adult patients with moder-
ately-to-severely active UC who were naive to bi-
ologics was performed by Danese et al. [53]. They 
obtained results similar to ours; in particular, they 
found that infliximab was more effective in induc-
ing a clinical response and mucosal healing than 
adalimumab in the induction phase. For inducing 
a clinical response, the odds ratio was 2.36 (95% CI: 
1.22–4.63), and for mucosal healing, it was 2.02 
(95% CI: 1.13–3.59).
Calculations in the indirect comparison were 
based on published study results instead of in-
dividual patient data, which may generate bias. 
Despite the fact that populations from the in-
cluded studies were quite homogeneous in their 
characteristics – mean age in each group, wom-
en-to-men ratio, degree of UC (Mayo score) and 
inflammation (C-reactive protein levels), and defi-
nitions of the inclusion criteria and selected study 
endpoints were similar, there were important dif-
ferences that might have affected the results of 
the indirect comparison between infliximab and 
adalimumab treatments. As shown in Table II, 
first, patients were allowed to use concomitant 
medications in clinical trials, and only in the inflix-
imab-treated population did they receive high lev-
els of corticosteroids (≥ 20 mg/day), which might 
have affected the results for infliximab treatment, 
and it may explain why infliximab seems to have 
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better efficacy than adalimumab in the induction 
phase of drug administration. Second, the mean 
duration of disease from onset was longer in pa-
tients treated with adalimumab, and this might 
also have interfered with our results.
The strengths of this systematic review include 
strict methodology based on the methods and rec-
ommendations from the PRISMA Statement [23] 
and Cochrane Handbook [24], concerning a clear 
search strategy and predefined inclusion criteria 
for studies to be included in a systematic review 
and meta-analysis. Furthermore, only RCTs were 
taken into consideration. Data extraction and cal-
culations were performed independently by two 
authors. The analysis depending on the heteroge-
neity of data and an appropriate statistical model 
was applied (fixed- or random-effects) [3]. This 
systematic review and indirect comparison also 
included data for the most important clinical out-
comes in terms of the efficacy and safety of the bi-
ologic therapy and individual biologics in patients 
with moderately-to-severely active UC. Finally, it 
included a new biologic, golimumab, recently ap-
proved by the FDA [16] and the EMA [17] for this 
particular indication. 
The compared datasets included data only 
from randomized, double-blind, placebo-con-
trolled and parallel RCT phase II/III studies. Results 
from nonrandomized or uncontrolled open-label 
studies were not incorporated into the dataset 
[1]. The population of interest included patients 
with moderately-to-severely active UC treated 
with anti-TNF-α agents: infliximab, adalimumab, 
and golimumab. A diagnosis of UC was confirmed 
by biopsy and was defined as a Mayo score rang-
ing from 6 to 12 points with an endoscopy sub-
score of at least 2. Eligible populations of patients 
were adults with a  biopsy-established diagnosis 
of moderately-to-severely active UC despite con-
current treatment with stable doses of oral cor-
ticosteroids or immunomodulators (such as aza-
thioprine or 6-mercaptopurine), or both. Patients 
concurrently treated with oral corticosteroids or 
immunomodulators were receiving a stable dose 
prior to baseline. Concurrent therapy was not re-
quired for patients who failed to respond to or 
could not tolerate previous corticosteroid or im-
munomodulator treatment, as assessed by the in-
vestigator. Patients who received infliximab, adali-
mumab, golimumab, or any other anti-TNF therapy 
in the past were not eligible. The key exclusion 
criteria included a history of colectomy or planned 
bowel surgery, ongoing infections (in particular 
confirmed tuberculosis), or the use of any inves-
tigational agent within 30 days or five half-lives 
prior to baseline.
We excluded a  clinical trial by Jarnerot et al. 
[54], which was one of the search results for in-
fliximab studies. The reason was that population 
characteristics when the treatment was used only 
in patients with a positive fulminant colitis index 
or in those demonstrating a severe or moderately 
severe attack of UC not responding to corticoste-
roid treatment were different from those analyzed 
in our meta-analysis. Patients in this population 
[52] had strong inflammation: the median C-reac-
tive protein value was 65 mg/l in the infliximab 
group and 44 mg/l in the placebo group, in com-
parison to 8 mg/l and 7 mg/l for the infliximab 
and placebo groups, respectively, in the ACT-1 and 
ACT-2 studies [37, 38] as well as in comparison 
with patients in the included studies on adalim-
umab or golimumab. 
Despite the above limitations, this system-
atic review and indirect comparison enabled us 
to compare the effectiveness of infliximab vs. 
adalimumab and infliximab vs. golimumab in 
patients with moderately-to-severely active UC. 
The growing number of patients with UC impos-
es the need to develop new agents to effectively 
induce and maintain remission, improve quali-
ty of life, and prevent colectomy in this patient 
group.
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